Atlas Trials

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Clinical trial NCT02910557 · COMPLETED

Trial details

NCT number
NCT02910557
Sponsor
Amgen
Status
COMPLETED
Study type
OBSERVATIONAL
MelanomaHerpetic Infection
Start date
2017-08-10
Primary completion
2026-01-30
Enrollment
187

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.